Wells Fargo & Co Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA)‘s stock had its “buy” rating restated by research analysts at Wells Fargo & Co in a report issued on Monday. They currently have a $23.00 target price on the biotechnology company’s stock. Wells Fargo & Co’s target price would suggest a potential upside of 59.72% from the stock’s previous close.

Several other equities analysts have also issued reports on the company. HC Wainwright set a $16.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. BidaskClub lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Oppenheimer set a $13.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Jefferies Group reiterated a “buy” rating on shares of Iovance Biotherapeutics in a research note on Sunday, October 29th. Finally, FBR & Co reiterated a “buy” rating and issued a $17.50 target price on shares of Iovance Biotherapeutics in a research note on Wednesday, October 25th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $16.15.

Iovance Biotherapeutics (NASDAQ IOVA) traded up $0.70 during mid-day trading on Monday, hitting $14.40. The company had a trading volume of 1,890,000 shares, compared to its average volume of 969,882. The company has a market capitalization of $1,050.00, a P/E ratio of -10.99 and a beta of 4.89. Iovance Biotherapeutics has a 12-month low of $4.45 and a 12-month high of $15.10.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). sell-side analysts forecast that Iovance Biotherapeutics will post -1.35 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of Iovance Biotherapeutics during the second quarter worth about $103,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Iovance Biotherapeutics during the second quarter worth about $125,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Iovance Biotherapeutics during the third quarter worth about $133,000. Edge Wealth Management LLC purchased a new stake in shares of Iovance Biotherapeutics during the third quarter worth about $150,000. Finally, People s United Financial Inc. purchased a new stake in shares of Iovance Biotherapeutics during the second quarter worth about $143,000. Institutional investors and hedge funds own 76.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/29/wells-fargo-co-reiterates-buy-rating-for-iovance-biotherapeutics-iova.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply